Briefing Summary: US FDA Posts Advisory Committee Materials for Eli Lilly’s Necitumumab for Squamous Non-small Cell Lung Cancer – JUL 9, 2015 (ODAC)
The US FDA has posted details, including company and FDA Briefing Materials, for the Thursday, July 9, 2015 Oncologic Drugs Advisory Committee (ODAC) meeting. The Committee will discuss biologics license application 125547, necitumumab injection, submitted by Eli Lilly and Company. The proposed indication for this product is in combination with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer.